DSM-Firmenich stock sits 0.21 percent below its 52-week high

Published on 10/15/2026 at 10:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half adjusted EBITDA reached EUR 900 million. DSM-Firmenich stock costs EUR 105.23 on October 15, 2026 versus EUR 105.00 Xetra close.

Capital return and operating margins

The company completed a EUR 540.0 million share repurchase program on October 1, 2026.
First-half 2026 adjusted EBITDA reached EUR 900.0 million on revenue of EUR 4.66 billion.
DSM-Firmenich stock trades at EUR 105.23 at 10:34 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.22 percent above the Xetra close of October 14, 2026.

Fotorealistisches Duftlabor mit Wissenschaftlern und Destillationsanlagen — dsm-firmenich AG (ISIN CH1216478797) betreibt moderne Duftlabore mit Wissenschaftlern und Analysegeräten für Aromastoffe, Illustration mit AI erstellt.

DSM-Firmenich (ISIN CH1216478797) was trading at EUR 105.23 at Lang & Schwarz on October 15, 2026 at 10:34 a.m. CEST, up EUR 0.23 or 0.22 percent versus the Xetra close of October 14, 2026 at EUR 105.00. The latest company action was the completion of a EUR 540 million share repurchase program on October 1, 2026, according to dsm-firmenich.

Three milestones shape the picture

The company said on October 1, 2026 that it had repurchased 7,169,147 shares at an average price of EUR 75.32. It plans to cancel 6,488,446 shares by the end of the first quarter of 2027, reducing issued shares by 2.6 percent from 253,626,947 to 247,138,501, according to dsm-firmenich.

In chronological order, the company reported first-half revenue of EUR 4.66 billion and adjusted EBITDA of EUR 900 million on July 30, 2026. Citi raised its price target from EUR 106.00 to EUR 111.00 on September 25, 2026, as reported by MarketWatch. The buyback completion followed on October 1, 2026 with a EUR 540 million total consideration.

What does the 19.3 percent margin mean?

The first-half 2026 adjusted EBITDA margin was 19.3 percent, compared with the company's approximately 20 percent full-year 2026 objective. The comparison points to a narrow operating gap, while the 2.6 percent planned share-count reduction could increase the effect of future earnings on each remaining share. The figures come from De Belegger, which reported 5 percent comparable revenue growth in the first half and 6 percent in the second quarter.

Next company date is October 28

The next dated company event identified is SupplySide Global 2026 on October 28, 2026. DSM-Firmenich lists the event in its Health, Nutrition and Care news center, alongside a September 29, 2026 launch of its Biond platform, according to dsm-firmenich.

Stock stays below its yearly high

At EUR 105.23, the stock stood EUR 0.22 below its 52-week high of EUR 105.45 and EUR 50.01 above its 52-week low of EUR 55.22, both as of October 15, 2026. The current market capitalization was EUR 25.7 billion.

DSM-Firmenich was trading at EUR 105.23 at Lang & Schwarz on October 15, 2026 at 10:34 a.m. CEST, 0.22 percent above the Xetra close of October 14, 2026 at EUR 105.00. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.